Slope Launches Tech-Enabled Services to Bolster Biospecimen Lifecycle Management in Clinical Trials

New tech-enabled services empower pharmaceutical companies to optimize biospecimen operations and data management, transforming sample data into actionable insights

RICHMOND, Va., Sept. 10, 2024 /PRNewswire/ — Slope, a global provider of biospecimen lifecycle software, data, and services for clinical trials, today announced the launch of a premium suite of services designed to empower clinical trial sponsors to harness the full potential of their biospecimen data from study startup to closeout.

Slope’s services empower clinical trial sponsors to harness the full potential of their biospecimen data.

“Our sponsor customers of Slope’s biospecimen lifecycle software, Biospecimen360™, already receive guidance from our team of experts along every touchpoint of the biospecimen lifecycle,” said Mark Melton, VP of Biospecimen Data and Operations at Slope. “Our new tech-enabled services elevate this support, ensuring our sponsors are actualizing the immense value of their sample data.”

Slope’s new Professional Services are a premium, customizable set of offerings that extend beyond the setup, execution, and optimization support offered to every customer. Collectively, Slope’s services support the following functions:

  • Lab & Biospecimen Operations: Slope provides deep expertise in protocol design, vendor selection, and sample collection workflows. By offering strategic guidance and operational oversight, these services help streamline trial execution, maintain quality standards, and meet critical timelines.
  • End-to-End Sample Tracking: Slope delivers robust monitoring and reconciliation of biospecimen movement and metadata. These services ensure accurate, real-time tracking throughout the biospecimen lifecycle, minimizing deviations and safeguarding sample integrity.
  • Biospecimen Data Management: From study setup to final database lock, Slope oversees all aspects of sample metadata. These services ensure rigorous data governance, data integrity, seamless data transfers, and streamlined reconciliation processes — all of which are essential for ensuring protocol endpoints are hit.

“We recognize the profound impact of controlling kit inventory, sample collection, processing, and shipment in a single platform on all stakeholders involved in a clinical trial,” added Melton. “With Slope’s new suite of services, you don’t just get quicker access to more high-quality data — you get the expertise to optimize your data and transform that data into actionable insights — driving better decisions and more efficient trials.”

Slope’s tech-enabled services provide a cost-effective, high-impact solution for pharmaceutical companies facing the challenges of complex, sample-intensive trials. By combining Biospecimen360™ with expert support, Slope empowers sponsors to unlock the full potential of their biospecimen data, ensuring that every decision is informed by real-time, high-quality information.

For more information, visit slopeclinical.com.

About Slope

Slope is a global provider of biospecimen lifecycle software, data, and services for clinical trials. With a focus on tech-enabling the full biospecimen lifecycle, Slope offers expertise that empowers sponsors to make informed decisions using high-quality, real-time sample data. Slope has supported thousands of the most complex, sample-intensive trials worldwide and has been adopted by nearly 80% of NCI-designated cancer centers. For more information, visit slopeclinical.com.

Media Contact
Fay Li
Praxcomm Strategies for Slope
fay@praxcomm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/slope-launches-tech-enabled-services-to-bolster-biospecimen-lifecycle-management-in-clinical-trials-302242764.html

SOURCE Slope

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

6 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

9 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

9 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

9 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

9 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

9 hours ago